Stay updated with breaking news from Sam Slutsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode.
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $34.00....
In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Rain Therapeutics (RAIN – Research Report). The c...
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Rain Therapeutics (RAIN – Research Report)...
Operator: Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.